
Redefining targeted immunotherapy in multiple myeloma through antigen innovation
Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, explores how discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias. For more than two decades, progress in multiple myeloma has been marked by sustained advances in drug development that have not translated… Read More















